Insulin resistance as a predictor of polymorbidity. Pathogenetic therapy (review)
The phenomenon of insulin resistance as a factor of polymorbidity is increasingly discussed in the literature. The evidence base on the pathogenetic role of insulin resistance for the formation of a number of socially significant diseases that reduce the quality and life expectancy of patients has been accumulated. The role of cellular transporter proteins in the regulation of glucose metabolism as one of the links of therapeutic action is discussed. Attention is focused on the effect of insulin on the processes of neurogenesis, its angio- and neuroprotective properties. The levels of insulin resistance development that determine the optimization of pharmacotherapeutic effects, the choice of the most accessible method for determining insulin resistance for clinical and outpatient conditions, the evaluation of the results of which will allow evaluating the effectiveness of the treatment. Various methods of determining this pathology are proposed and new approaches to its treatment are being sought. This article provides an overview of the existing information about the currently known pathogenetic mechanisms of insulin resistance, as well as the methods used in clinical practice for its diagnosis and therapeutic correction. An overview of the most modern and promising oral hypoglycemic drugs and their pleotropic effects is given.
Golivets T.P., Likrizon S.V., Dubonosova D.G. 2022. Insulin resistance as a predictor of polymorbidity (review). Pathogenetic therapy. Challenges in Modern Medicine. 45 (1): 5–19 (in Russian). DOI: 10.52575/2687-0940-2022-45-1-5-19
While nobody left any comments to this publication.
You can be first.
Artymuk N.V., Tachkova O.A. 2021. Novoe o patogeneze i lechenii sindroma polikistoznyh yaichnikov [New information about the pathogenesis and treatment of polycystic ovary syndrome]. RMZH. 1: 17–22.
Dedov I.I., Mel'nichenko G.A. 2018. Endokrinologiya: nacional'noe rukovodstvo [Endocrinology. National leadership]. 2-e izd., pererab. i dop. – Moskva: GEOTAR-Media. 1112 s. il. 1112 s. URL: https://www.rosmedlib.ru/book/ISBN9785970446041.html. (data obrashcheniya: 19.12.2021).
Dedov I.I., Shestakova M.V., Majorov A.Yu. 2019. Klinicheskie rekomendacii. Algoritmy specializirovannoj medicinskoj pomoshchi bol'nym saharnym diabetom [Clinical recommendations. Algorithms of specialized medical care for patients with diabetes mellitus]. 9-j vypusk. Moskva; 22(S1) DOI: 10.14341/DM221S1.
Dedov I.I., Shestakova M.V., Vikulova O.K. 2017. Epidemiologiya saharnogo diabeta v Rossijskoj Federacii: kliniko-statisticheskij analiz po dannym Federal'nogo registra saharnogo diabeta [Epidemiology of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal Register of Diabetes Mellitus]. Saharnyj diabet. 20 (1): 13–41.
Demidova T.Yu., Zenina S.G. 2019. Rol' insulinorezistentnosti v razvitii saharnogo diabeta i drugih sostoyanij. Sovremennye vozmozhnosti korrekcii [The role of insulin resistance in the development of diabetes mellitus and other conditions. Modern correction capabilities]. RMZH. 10: 116–122.
Demidova T.Yu. 2010. Etiopatogeneticheskaya rol' insulinorezistentnosti v razvitii metabolicheskih i sosudistyh narushenij pri saharnom diabete 2 tipa [Etiopathogenetic role of insulin resistance in the development of metabolic and vascular disorders in type 2 diabetes mellitus]. Farmateka. 16 (210): 18–24.
Demidova T.Yu., Kishkovich Yu.S. 2019. Prediabet: sovremennoe sostoyanie problemy i vozmozhnosti korrekcii [Prediabetes: the current state of the problem and the possibilities of correction]. RMZH. 10(II): 60–67.
Demidova T.Yu., Plahotnyaya V.M., Grickevich E.Yu. 2020. Patogeneticheskie podhody k vedeniyu pacientov s saharnym diabetom 2 tipa. Novye potrebnosti i novye vozmozhnosti [Pathogenetic approaches to the management of patients with type 2 diabetes mellitus. New needs and new opportunities]. RMZH. 6: 347–351.
Dreval' A.V. 2018. Diabetologicheskaya praktika [Diabetic practice]. Moskva: GEOTAR-Media. 544 s. URL: https://www.rosmedlib.ru/book/ISBN9785970441930.html (data obrashcheniya: 19.12.2021).
Egshatyan L.V. 2018. Neklassicheskie effekty vitamina D [Non-classical effects of vitamin D]. Ozhirenie i metabolizm. 15 (1): 12–18.
Kondrat'eva L.V., Ivanova L.P. 2017. Metformin v terapii metabolicheskih narushenij: glikemicheskie i neglikemicheskie effekty [Metformin in the treatment of metabolic disorders: glycemic and non-glycemic effects]. Endokrinologiya. 2: 22–27.
Makisheva R.T. 2016. Adaptivnyj smysl insulinorezistentnosti [Adaptive meaning of insulin resistance]. Vestnik medicinskih tekhnologij. 1: 61–67.
Pashenceva A.V., Verbovoj A.F., Sharonova L.A. 2017. Insulinorezistentnost' v terapevticheskoj klinike [Insulin resistance in a therapeutic clinic]. Ozhirenie i metabolizm. 9–17.
Suplotova L.A., Avdeeva V.A., Rozhinskaya L.Ya. 2021. K voprosu o patogeneticheskih mekhanizmah vliyaniya ozhireniya na uroven' vitamina D [On the pathogenetic mechanisms of the effect of obesity on vitamin D levels]. Ozhirenie i metabolizm. 18 (2): 169–174.
Tkachenko L.I., Maleev V.V. 2016. Insulinorezistentnost' i hronicheskij gepatit C [Insulin resistance and chronic hepatitis C]. Terapevticheskij arhiv. 88 (11): 29–36.
Chzhou Yu., Hembli B.D., Maklahan K.S. 2017. Svyaz' FTO s ozhireniem i dlinoj telomere [The relationship of FTO with obesity and telomere length]. Zhurnal Biomedicinskih nauk. 2: 21–28.
Brozovich F.V., Nicholson C.J., Degen C.V., Yuan Z. Gao, Aggarwal M., Morgan K.G. 2016. Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders. Pharmacol Rev 68:476–532. doi.org/10.1124/pr.115.010652
Diabetes Prevention Program Research Group. 2015. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 3(11): 866–875.
Gutiérrez-Rodelo C., Roura-Guiberna A., Olivares-Reyes А.J. 2017. Molecular Mechanisms of Insulin Resistance: An Update. Gac. Med. Mex. 153 (2): 214–228.
Haddad D., Al Madhoun A., Nizam R., Al-Mulla F. 2020. Role of Caveolin-1 in Diabetes and Its Complications. Oxid. Med. Cell. Longev. 9761539. doi: 10.1155/2020/9761539
Herold J., Kalucka J. 2021. Angiogenesis in Adipose Tissue: The Interplay Between Adipose and Endothelial Cells. Front. Physiol. 11: 624903. doi: 10.3389/fphys.2020.624903
Hyeon-Jeong Hwang, Kyoung-Su Park, Jang Hyun Choi, Lucio Cocco, Hyun-Jun Jang, Pann-Ghill Suh. 2018. Zafirlukast promotes insulin secretion by increasing calcium influx through L-type calcium channels. J. Cell. Physiol. 233 (11): 8701–8710. doi: 10.1002/jcp.26750.
Kleinridders A., Ferris H.A., Cai W., Kahn C.R. 2014. Insulin action in brain regulates systemic metabolism and brain function. Diabetes. 63 (7): 2232–43.
Kuboki K., Jiang Z.Y., Takahara N. 2000. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation. 101: 676–681.
Matsuda M., DeFronzo R.A. 1999. Diabetes Care. 22: 1462–1470.
Mkrtumyan A., Romantsova T., Vorobiev S., Volkova A., Vorokhobina N., Tarasov S., Putilovskiy M., Andrianova E., Epstein O. 2018. Efficacy and safety of Subetta add-on therapy in type 1 diabetes mellitus: The results of a multicenter, double-blind, placebo-controlled, randomized clinical trial. Diabetes Res Clin Pract. 142: 1-9. DOI: 10.1016/j.diabres.2018.04.044
Mokhtari E., Teymoori F., Farhadnejad H., Mirmiran P., Azizi F. 2022. Development and validation of dietary and lifestyle insulinemic indices among Iranian adult population. Nutr Metab (Lond). 19 (1): 5. doi: 10.1186/s12986-021-00640-6
Munwar S., Ilango K. 2020. The Journey of Thiazolidinediones as Modulators of PPARs for the Management of Diabetes: A Critical Review. Med. Chem. (Los Angeles). 10: 5. DOI: 10.37421/mccr.2020.10.547.
Ormazabal V., Nair S., Elfeky O., Claudio A., Carlos S., Felipe A.Z. 2018. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol 17, 122. doi.org/10.1186/s12933-018-0762-4
Spinelli M., Fusco S. and Grassi C. 2019. Brain Insulin Resistance and Hippocampal Plasticity: Mechanisms and Biomarkers of Cognitive Decline. Front. Neurosci. 13: 788. doi: 10.3389/fnins.2019.00788
Sposato V., Canu N., Fico E., Fusco S., Bolasco G., Ciotti M.T. 2019. The medial septum is insulin resistant in the AD presymptomatic phase: rescue by nerve growth factor-driven IRS1 activation. Mol. Neurobiol. 56, 535–552. doi: 10.1007/s12035-018-1038-4
Sushko О.О., Iskra R.J., & Ponkalo L.I. 2019. Influence of chromium citrate on oxidative stress in the tissues of muscle and kidney of rats with experimentally induced diabetes. Regulatory Mechanisms in Biosystems, 10 (2), 209–214. doi:10.15421/0219231
Vitale С., Mercuro G., Castiglioni C. 2005. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc. Diabetol. 4: 6–11.
William R. Hiatt, Sanjay Kaul, Robert J. Smith. 2013. The Cardiovascular Safety of Diabetes Drugs – Insights from the Rosiglitazone Experience. N. Engl. J. Med. 2013; 369: 1285–1287. DOI: 10.1056/NEJMp1309610
Xourgia E., Papazafiropoulou A., Melidonis A. 2019. Antidiabetic treatment on memory and spatial learning: From the pancreas to the neuron. World. J. Diabetes. 10 (3): 169–180 DOI: 10.4239/wjd.v10.i3.169
Zhou L., Liu H., Wen X. 2017. Effects of metformin on blood pressure in nondiabetic patients. J. Hypertens. 35 (1): 18–26.
Zhu Y., Liu Q., Zhou Z., Ikeda Y. 2017. PDX1, Neurogenin-3, and MAFA: critical transcription regulators for beta cell development and regeneration. Stem. Cell. Res. Ther. 8 (1): 240.